NCT04359849

Brief Summary

The Investigators plan to generate a database of viral RNA sequences for SARS-CoV-2 within the Wessex region. Such whole genome data can be used to monitor mutation rates in real time and, through comparison with global databases of SARS-CoV-2 genome sequences, can be used to map transmission of the virus

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5,602

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2020

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 20, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 24, 2020

Completed
10 days until next milestone

Study Start

First participant enrolled

May 4, 2020

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2022

Completed
Last Updated

April 3, 2023

Status Verified

January 1, 2023

Enrollment Period

2.4 years

First QC Date

April 20, 2020

Last Update Submit

March 30, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of whole genome sequences for the SARS-CoV-2 virus from viral RNA samples

    Generated using Nanopore-based whole genome sequencing techniques

    2 years

Secondary Outcomes (1)

  • Transmission rates of the SARS-CoV-2 virus

    2 years

Eligibility Criteria

Age7 Years+
Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Focus on those whose tests have provided a positive result so as to maximise the number of SARS-CoV-2 genomes generated.

You may qualify if:

  • Have undergone successful testing for Covid-19
  • Have sufficient viral RNA remaining for research analysis following testing for Covid-19

You may not qualify if:

  • Insufficient viral RNA remains following testing for Covid-19

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Portsmouth Hospitals NHS Trust, Queen Alexandra Hospital

Portsmouth, Hampshire, PO6 3LY, United Kingdom

Location

MeSH Terms

Conditions

Coronavirus Infections

Condition Hierarchy (Ancestors)

Coronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsVirus DiseasesInfections

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 20, 2020

First Posted

April 24, 2020

Study Start

May 4, 2020

Primary Completion

September 30, 2022

Study Completion

September 30, 2022

Last Updated

April 3, 2023

Record last verified: 2023-01

Locations